<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="114627">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01610947</url>
  </required_header>
  <id_info>
    <org_study_id>8785</org_study_id>
    <nct_id>NCT01610947</nct_id>
  </id_info>
  <brief_title>Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity</brief_title>
  <acronym>SPACING</acronym>
  <official_title>Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity: a Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Montpellier</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Montpellier</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with spondyloarthritis, already treated by TNF blocker (adalimumab, etanercept or
      infliximab), and in stable low disease activity for at least 6 months, will be randomized
      into 2 groups: either keeping on their usual treatment with stable doses or progressive
      spacing of injections of their treatment. Follow-up will be done every 3 months during 12
      months, with regular monitoring of disease activity and, in patients from the group
      &quot;spacing&quot;, modification of the rhythm of injections according to health state and predefined
      protocol.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients remaining in low disease activity</measure>
    <time_frame>12 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Medico-economic comparison of arms</measure>
    <time_frame>12 months</time_frame>
    <description>The cost-efficacy ratio will be compared between the 2 arms (maintain and spacing). The objective is to see if the spacing of the treatments will allow a better tolerance and reduce the cost due to the treatments.To assess this cost-efficacy ratio, questionnaires will be used (quality of life SF36, medico-economic Euroqol).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">398</enrollment>
  <condition>Spondyloarthritis</condition>
  <arm_group>
    <arm_group_label>Maintain</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continuation of usual treatment with fixed intervals according to standard recommendations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Spacing</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab, Etanercept, Golimumab or infliximab</intervention_name>
    <description>Continuation of usual treatment with fixed intervals according to standard recommendations</description>
    <arm_group_label>Maintain</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adalimumab, Etanercept, Golimumab or infliximab</intervention_name>
    <description>Progressive spacing of injections according to disease activity observed during follow-up and predefined protocol</description>
    <arm_group_label>Spacing</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult patients with spondyloarthritis according to ASAS criteria

          -  Stable low disease activity for at least 6 months

          -  Already treated by TNF blocking drug (adalimumab, etanercept or infliximab)

        Exclusion Criteria:

          -  Raised acute phase reactants

          -  participation in another clinical trial

          -  Structural progression of peripheral joint damage

          -  Scheduled surgery within 12 months

          -  pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Cédric Lukas, MD PhD</last_name>
    <phone>+33627572161</phone>
    <email>c-lukas@chu-montpellier.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lapeyronie Hospital</name>
      <address>
        <city>Montpellier</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cédric Lukas, MD PhD</last_name>
      <phone>+33627572161</phone>
      <email>c-lukas@chu-montpellier.fr</email>
    </contact>
    <investigator>
      <last_name>Cédric Lukas, Md PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>November 2015</verification_date>
  <lastchanged_date>November 23, 2015</lastchanged_date>
  <firstreceived_date>May 24, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Spondyloarthritis</keyword>
  <keyword>Anti-TNF</keyword>
  <keyword>Adalimumab</keyword>
  <keyword>Etanercept</keyword>
  <keyword>Infliximab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Spondylitis</mesh_term>
    <mesh_term>Spondylitis, Ankylosing</mesh_term>
    <mesh_term>Spondylarthritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
    <mesh_term>Etanercept</mesh_term>
    <mesh_term>Adalimumab</mesh_term>
    <mesh_term>Infliximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
